Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its ...
ClearVue Technologies (ASX:CPV) has secured $881,000 in an Australian government R&D tax rebate, consequently repaying its ...
Sino Biopharmaceutical ( (HK:1177)) has shared an update. Sino Biopharmaceutical Limited announced that its innovative drug, LM-350 ‘CDH17 ADC’, has received clinical trial approval from China’s ...
Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases. The asset in question, ...
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback